Small molecule · Cytotoxic, directed at DNA and topoisomerase II (TOP2A) · developed by Pfizer
Idarubicin is a semisynthetic anthracycline, a 4-demethoxy analogue of daunorubicin, that intercalates into DNA and inhibits topoisomerase II, interfering with DNA replication, RNA transcription and protein synthesis. It is studied in acute myeloid leukemia (AML), including AML with NPM1 mutation and KMT2A rearrangement.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 15, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05586074 | Phase 3 | Leukemia, Acute Myeloid (AML) | Recruiting | SBFM |
| NCT06001788 | Phase 1 | AML | Recruiting | KURA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute LeukemiaAcute Myeloid LeukemiaAMLAML With Mutated NPM1Hematologic MalignancyKMT2ArLeukemiaLeukemia, Acute Myeloid (AML)Leukemia, MyeloidLeukemia, Myeloid, AcuteMLL RearrangementNeoplasms by Histologic TypeNPM1 Mutation
Updated Nov 1, 2026.